External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ISPOR 2026

-
08:00 PM
Duration 180mins Philadelphia, USA
Clinical and Economic Impact of Faricimab▼-Treated Diabetic Macular Edema: A Linked Analysis of Administrative Claims and IRIS Registry Data
Nicole Gidaya Bonine, Stella Ko, Xiaowu Sun, Jessica Clubb, Ayesha Ahmed, Bryan Moore, Laura Lupton, Dingwei Dai, Yi Liu, Yimin Wu, Blake A. Cooper
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:00 PM
Duration 180mins Philadelphia, USA
Impact of Lupus Nephritis Flares on Healthcare Utilization: A Retrospective Cohort Study in the United States between 2016 and 2025
Jiying Zou, Huong Trinh, Jesse Sussell, Shu Wang, Anisha M. Patel, William F. Pendergraft III, Lisa Lindsay
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:30 PM
Duration 180mins Philadelphia, USA
The Value Vocabulary: An Analysis of Societal Terms in Health Technology Assessment Decision Making
Jessica Moreira, Lori Yin, Chaim Simon Yunger, Jean-Éric Tarride
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 180mins Philadelphia, USA
Understanding the Impact and Burden of Menopause on Multiple Sclerosis Through a Targeted Literature Review
Jain, Divya, Ravelo Arliene, Abioye, Ibraheem, Pineda, Elmor D.
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:00 PM
Duration 180mins Philadelphia, USA
Novel therapies for relapsed/refractory mantle cell lymphoma post Bruton’s tyrosine kinase inhibitor: A targeted literature review
Weisman N, Lo-Rossi A, Lin C-W, Reyes C
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 180mins Philadelphia, USA
Cost-effectiveness of subcutaneous mosunetuzumab ▼ plus polatuzumab vedotin versus rituximab plus gemcitabine and oxaliplatin for United States (US) patients with autologous stem cell transplant-ineligible relapsed/refractory large B-cell lymphoma (LBCL)
Westin J, Rosettie KL, Masaquel A, Elsea D, Celik H, Seo M, Lai D, Lo-Rossi A, Flowers C
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:00 PM
Duration 180mins Philadelphia, USA
Dynamic Pricing in the Context of Cost-Effectiveness Modeling and Willingness-to-Pay Thresholds
Juha Raino Laine, Katherine Rosettie
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 150mins Philadelphia, USA
The total cost of care and budget impact of introducing mosunetuzumab ▼ plus polatuzumab vedotin for second-line or later (2L+) treatment of relapsed/refractory large B-cell lymphoma (LBCL) to a United States (US) health plan
Westin J, Elsea D, Rosettie KL, Masaquel A, Lo-Rossi A, Lai D, Flowers C
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 150mins Philadelphia, USA
Measuring Adherence to, and Persistence with, Advanced Therapy in US Patients with Lupus Nephritis in the Real-World Setting
Jesse Sussell, Anisha M. Patel, Achal Patel, Robert Schuldt, William F. Pendergraft III
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon